|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 95.10 USD | +0.16% |
|
-11.41% | +21.15% |
Business description: Mesa Laboratories, Inc.
Number of employees: 717
Sales by Activity: Mesa Laboratories, Inc.
| Fiscal Period: March | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) | 2026 (USD) |
|---|---|---|---|---|---|
Sterilization and Disinfection Control | 59.04M | 64.61M | 75.12M | 93.42M | 102M |
Calibration Solutions | 46.87M | 44.81M | 47.76M | 51.75M | 53.55M |
Biopharmaceutical Development | 45.58M | 47.36M | 40.71M | 48.73M | 48.63M |
Clinical Genomics | 32.84M | 62.3M | 52.59M | 47.08M | 45.39M |
Geographical breakdown of sales: Mesa Laboratories, Inc.
| Fiscal Period: March | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) | 2026 (USD) |
|---|---|---|---|---|---|
United States | 99.07M | 117M | 106M | 117M | 117M |
Other | - | 76M | 84.86M | 99.05M | 112M |
China | - | 25.8M | 24.93M | 25.31M | 20.45M |
Foreign | 85.27M | - | - | - | - |
Executive Committee: Mesa Laboratories, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Siddhartha Kadia
CEO | Chief Executive Officer | 56 | 2026-04-11 |
John Sakys
DFI | Director of Finance/CFO | 57 | 2012-10-28 |
Lyndsey Crennen
AUD | Comptroller/Controller/Auditor | 41 | 2021-12-31 |
Paul Yates
PRN | Corporate Officer/Principal | - | 2020-04-30 |
Brian Archbold
PRN | Corporate Officer/Principal | 61 | 2017-12-31 |
Composition of the Board of Directors: Mesa Laboratories, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
John Sullivan
CHM | Chairman | 73 | 2017-08-31 |
Mark Capone
BRD | Director/Board Member | 63 | 2024-01-04 |
R. Tripeny
BRD | Director/Board Member | 67 | 2022-06-22 |
Siddhartha Kadia
BRD | Director/Board Member | 56 | 2026-04-11 |
Shannon Hall
BRD | Director/Board Member | 57 | 2020-05-10 |
Shiraz Ladiwala
BRD | Director/Board Member | 60 | 2021-10-27 |
Jennifer Alltoft
BRD | Director/Board Member | 57 | 2019-03-03 |
Company details: Mesa Laboratories, Inc.
Group companies: Mesa Laboratories, Inc.
| Name | Category and Sector |
|---|---|
Mesa France SAS
 Mesa France SAS Medical DistributorsDistribution Services Distributes biological indicator products |
Medical Distributors
|
Other Medical Equipment, Supplies & Distribution
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | -11.41% | +2.27% | -29.84% | 525M | |
| -0.10% | -1.38% | -33.23% | -16.75% | 154B | |
| +1.54% | -1.23% | -7.45% | -11.00% | 102B | |
| -4.45% | +6.22% | +58.91% | +55.60% | 59.25B | |
| -1.90% | -3.43% | -8.40% | +48.53% | 52.89B | |
| +1.67% | -2.29% | -14.60% | -44.33% | 39.67B | |
| -1.32% | -3.20% | - | - | 30.39B | |
| +1.74% | -3.69% | -10.54% | -44.30% | 27.96B | |
| -1.25% | -0.72% | +50.47% | -9.42% | 23.17B | |
| -1.53% | -1.74% | -15.43% | -3.81% | 20.7B | |
| Average | -0.28% | -1.60% | +2.44% | -6.15% | 51.04B | |
| Weighted average by Cap. | -0.29% | -0.21% | -5.94% | -2.39% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MLAB Stock
- Company Mesa Laboratories, Inc.
Select your edition
All financial news and data tailored to specific country editions
